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A comparative study of antitumor activity of mono- and bis-quinoline based (thio)carbohydrazones was
investigated by a series of tests on two human malignant cell lines: acute monocytic leukemia (THP-1)
and pancreatic adenocarcinoma cancer stem cells (AsPC-1). Thiocarbohydrazones (TCHs) revealed
superior pro-apoptotic activity over carbohydrazones (CHs) on both tested cell phenotypes, also
displaying multi-target proﬁle activities. Programmed cell death triggered by TCHs was partially caspase-
dependent, mainly caspase-8 related. Activity against cancer stem cells (CSCs) was evaluated on 2D
monolayers and 3D spheroidal models, where two out of three tested bis-TCHs successfully stimulated
apoptosis accompanied by a reduction in size of treated spheres. Additionally, all bis-TCHs induced
signiﬁcant decrease in percentage of CD44-expressing AsPC-1 cells that indicate on their ability to
induce reprogramming of CSC phenotype. Current results highly support further assessment of bis-
TCHs in order to specify their speciﬁc targets in cancer cells and particularly in the CSCs subpopulation.Introduction
Hydrazones are condensation products of hydrazine or its alkyl,
acyl and aryl analogues with carbonyl compounds. They are
known to possess a broad spectrum of biological activities such
as antioxidant, analgesic, antiplatelet, antimicrobial, anticon-
vulsant, antidepressant, anti-inammatory, anti-tubercular,
cardio protective, anti-HIV, anthelmintic, anti-diabetic, trypa-
nocidal and anticancer activities.1–6 Many of these compounds
were patented in this respect.7 Monohydrazide derivatives of
carbonic and thiocarbonic acid, semicarbazide and thio-
semicarbazide, respectively react with N-heteroaromatic
carbonyl compounds giving (thio)semicarbazones – molecules
well described as tridentate NNO(S) chelators and ribonucleotidUniversity of Belgrade, Karnegijeva 4,
, Pasterova 14, Belgrade, Serbia
e, Studentski trg 12-16, Belgrade, Serbia
try, University of Belgrade, Studentski trg
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tion (ESI) available. See DOI:
hemistry 2016reductase (RR) inhibitory agents.8 RR plays a fundamental role
in the critical early events involved in tumor promotion and
activity of this enzyme is tightly linked to the neoplastic
expression state and is currently one of the main targets for
DNA inhibition by anticancer agents.9
The most studied hydrazone is triapine (3-amino-2-
formylpyridine thiosemicarbazone) since more than 30 clin-
ical phase I and phase II trials has been done so far.10 Triapine
was developed in 1994 as an RR inhibitor and its mechanism of
action was thought to be iron chelation from RR active site.11
Later on its iron(II) complex was supposed to be active species
which inhibits RR indirectly by generation of reactive oxygen
species (ROS) which are formed in Fentone type reactions.12
Recent evidences proved that iron(II) complex inhibits RR, but
probably via direct tyrosil radical quenching not involving
ROS.13 There are also diﬀerent theories were and how the active
Fe(II)–triapine complex is formed in the body. For example, one
study resulted in the model which proposed triapine binding
for RR surface, followed by labilization of the diferric center and
iron complex formation.14 On the other hand, there are
evidences that interaction of triapine with iron occurs in the
liver, which is known as the site of ferritin production.15 Unre-
vealing of triapine's mechanism of activity is still the topic of
interest. Recently mitochondria16,17 and endoplasmatic retic-
ulum18 were recognized as new triapine biological targets.
Carbohydrazide and thiocarbohydrazide are dihydrazide
derivatives of carbonic and thiocarbonic acids. As their mono-
hydrazide analogues (thio)semicarbazide, (thio)carbohydrazideRSC Adv., 2016, 6, 104763–104781 | 104763
Scheme 1 General procedure for the synthesis of carbohydrazones
O1–O6 and thiocarbohydrazones S1–S6.
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View Article Onlinealso form corresponding monohydrazones. The presence of
additional hydrazide group allows preparation of dihydrazones.
Despite the fact that mono- and bis-(thio)carbohydrazides are
also known to chelate iron,19–25 which make them potential RR
inhibitors, there are only few investigations published where
their anticancer activities were explored,25–33 with no study
about their possible mechanism of action.
Quinoline is a privileged scaﬀold in anticancer drug
discovery34 and various quinoline (thio)semicarbazones showed
promising results when tested against cancer cell lines.35–40 Here,
we present results of the rst systematically organized investiga-
tion of antitumor activity of three mono-carbohydrazones and
three mono-thiocarbohydrazones with their corresponding bis-
structural counterparts. Despite the development of new thera-
peutics with increasing success in treating malignancies, recur-
rence of disease can develop years aer eﬃcient therapy. It was
demonstrated that a small fraction of cells residing at the top of
genetic hierarchy within solid tumors, declared as cancer stem
cells (CSCs), are responsible for disease relapse.41 CSCs are also
assigned culpable for tumor growth, progression, dissemination
and resistance to therapy. Specied important role of CSCs in
tumor growth, metastases and relapse, dene that the major goal
in eﬀort to cure the cancer should be elimination or terminal
diﬀerentiation of CSCs. Currently, there is no available treatment
option proved as eﬃcient against this subpopulation of cancer
cells. Apart from having signicantly enhanced DNA repairing
mechanisms, CSCs hold a unique strategy to avoid the harmful
eﬀects of chemotherapeutic and radiation treatments which
exclusively aﬀect proliferating cells. There are several circum-
stances when CSCs resort the dormancy phase to gain genetic
and epigenetic alterations that are necessary for neoplastic
conversion, adaptation to new microenvironment and
survival.42,43 Therapy-induced dormancy describes response of
CSCs to repeated cycles of therapy that enter a dormant phase
and thereaer relapse as a more aggressive phenotype.44 To
eliminate CSCs, applied treatments should induce their apoptotic
death, or to interferes with their hideaway in dormancy phase by
stimulating mitotic division thus increasing their vulnerability to
chemo and radiotherapy. Therefore, in order to investigate ability
of our compounds to act as comprehensive anti-cancer agents
with competency to eliminate both CSCs and non-CSCs, current
biological study was organized on two diverse cell lines acute
monocytic leukemia (THP-1) and pancreatic adenocarcinoma
cancer stem cells (AsPC-1), where AsPC-1 cells are highly
expressing CSC phenotype.45,46 Additionally, alongside standardly
used 2D monolayer model, we here also used spheroidal 3D
culture as more accurate screening platform for drug activity
considering its architecture well mimics in vivo tumor mass.
Results and discussion
Chemistry
Carbohydrazones (CHs) O1–O6 and thiocarbohydrazones
(TCHs) S1–S6 were prepared by the condensation reaction of
carbonic acid dihydrazide (dhO) or its sulphur analogue thio-
carbonic acid dihydrazide (dhS) and appropriate aldehyde
(Scheme 1). The synthesis of O4 and S4 have been published104764 | RSC Adv., 2016, 6, 104763–104781earlier.47 The composition and purity of all compounds was
veried by elemental analysis, while their structural character-
ization was done by IR and NMR spectroscopy.
In order to optimize geometries of the all compounds DFT
calculations were performed. There are signicant structural
diﬀerences between optimized geometries of CHs and TCHs
(Table 1). Analogue monohydrazones diﬀer in the chalcogen
atom orientation, while in the case of bis-hydrazones symmet-
rical conformations were obtained in the case of CHs and
unsymmetrical ones in the case of TCHs. Optimized geometries
of bis-hydrazones are in accordance with data obtained by NMR
spectroscopy. Results of the GIAO/B3LYP calculations of the 1H
and 13C chemical shis of all compounds are shown in ESI
(Tables S1–S5†). Namely, the main diﬀerence between 1H NMR
spectra of oxygen based bis-hydrazones (bis-CHs) and sulphur
based bis-hydrazones (bis-TCHs) is presence of two distinct
signals for both, hydrazide and imine nitrogen protons in the
case of sulphur compounds. The presence of two distinct
signals for NH protons was already reported for bis-TCHs,48 and
that phenomenon was explained by the presence of intermo-
lecular hydrogen bonds between hydrazide hydrogen atom and
imine nitrogen atom, while in the case of bis-CHs there is no
such hydrogen bond.
All compounds obey Lipinski's rule of ve,49 (Table S6, ESI†)
so these compounds are drug-like, with promising bioavail-
ability and pharmacokinetics. The proton donating ability of
investigated quinoline based (thio)carbohydrazones O1–O6 and
S1–S6 was assayed using a protocol for the determination of
radical scavenging activity, the DPPH (1,1-diphenyl-2-
picrylhydrazyl radical) method.50 Ascorbic acid was used as
the reference compound (positive control). To the best of our
knowledge there is no systematic comparative study of free-
radical scavenging activity of CHs and TCHs. Our results indi-
cate that TCHs were far more active in DPPH radical scavenging
than their oxygen counterparts, with IC50 values close to that of
vitamin C (Table 1). In both group of compounds, those which
contain hydroxyl group are the most active, in the case of both
mono- and bis-hydrazones. It seems that the main reason for
pronounced antioxidant activity of TCHs is presence of thione
(C]S) group, since the obtained IC50 values are in the narrowThis journal is © The Royal Society of Chemistry 2016
Table 1 Optimized geometries of the compounds O1–O6 and S1–S6 and IC50 values (mM) determined by DPPH method
CHs IC50 (mM) TCHs IC50 (mM)
O1 0.87  0.11 S1 0.14  0.03
O2 16.40  1.02 S2 0.16  0.04
O3 0.67  0.06 S3 0.13  0.02
O4 10.50  0.46 S4 0.11  0.03
O5 0.21  0.05 S5 0.11  0.02
O6 1.50  0.09 S6 0.09  0.02
Ascorbic acid 0.08  0.01
Table 2 The ED50 concentrations (mM) achieved after 24 h treatment
of THP-1 and AsPC-1 cell lines with investigated CHs and TCHs.
Results are expressed as the mean  SD of two replicates from
independent experiments
CHs THP-1 AsPC-1 TCHs THP-1 AsPC-1
O1 n.d.a n.d. S1 8.4  0.3 n.d.
O2 35.2  0.7 64  4 S2 14  5 75  3
O3 n.d. n.d. S3 15.8  0.5 n.d.
O4 n.d. n.d. S4 2.4  0.2 n.d.
O5 n.d. n.d. S5 24  9 n.d.
O6 n.d. 57  2 S6 18  6 74  5
a n.d. – not determined in the range of applied concentrations (1–100 mM).
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View Article Onlinerange (0.09–0.16 mM), while S6 had almost the same activity as
vitamin C. Other thione antioxidants such as ergoteine and
thiosemicarbazones are well known for their free-radical scav-
enging activities.51,52 In the case of CHs, mono derivatives are 7–
19 times more active than their bis-hydrazone analogues, which
indicates a role of free –NH–NH2 group in the mechanism of
their antioxidant activity. More detailed study of antioxidant
activities of CHs and TCHs, which has a goal to decipher the
mechanism of action, is currently in progress in our group.
Investigation of anticancer activities
TCHs has substantially higher pro-apoptotic activity. Activity
of investigated compounds was evaluated aer 24 h incubation
with the cells, initially applied in a range of six concentrations
from 1–100 mM. In regard to structure–activity relationship, all
TCHs revealed pro-apoptotic activity on THP-1 cells, while
compound O2 was the only CH with ability to induce death on
this cell line (Table 2 and Fig. S1, ESI†). Contrary to O2, O6 was
another CH with activity against THP-1 cells, but yieldedThis journal is © The Royal Society of Chemistry 2016necrotic rather than apoptotic death, which was an obvious
reason to eliminate it from any further testings.
Apoptotic response in THP-1 cells treated with compound S4
was too drastic when added in the initial concentration range
and impeded determination of the dose–response curves andRSC Adv., 2016, 6, 104763–104781 | 104765
Fig. 1 Distribution within phases of mitotic division of THP-1 cells (A)
and AsPC-1 cells (B) determined after 24 h incubationwith investigated
compounds. Changes in cell cycle arrangement have been assessed in
the same samples previously analyzed for Annexin V/PI (results rep-
resented in Fig. S1 and S2, ESI†). Incidences of cells found at the G0/G1
(black), S (white) and G2/M (gray) phases were determined according
to non-treated control population. Results are represented as the
mean  SD of two replicates from independent experiments.
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View Article Onlinecomputation of ED50 concentration. Therefore, concentrations
of S4 had to be reduced to 0.5–30 mM (Fig. S1, ESI†). Compound
S4, as well as S1, dened bell-shaped dose–response curves with
the peak activities at 10 and 50 mM, respectively (Fig. S2A and
B†). Considering the percentage of cells stained by Annexin V,
the highest activity on THP-1 cells was achieved by O2 that
caused for almost all treated cells to be labeled with both
Annexin V and propidium iodide (PI) in samples subjected to
50, 75 and 100 mM, followed by a drastic decrease in cell death
events at already 30 mM (Fig. S1, ESI†). Such activity prole for
O2 was described with nearly vertical linear phase on dose–
response curve typical for drugs with a tight therapeutic
window, meaning that there is a narrow range of O2 concen-
trations that can achieve desired therapeutic eﬀect while
avoiding toxic threshold.
Contrary to the results obtained with THP-1 cells, only four
compounds displayed pro-apoptotic activity against pancreatic
AsPC-1 cells (Table 2 and Fig. S3, ESI†). Interestingly, those four
compounds are structural siblings, where O2 and O6 are CHs,
which analogically corresponds to TCHs S2 and S6, respectively.
Both compounds S6 and particularly S2 were revealed as less
eﬃcient against AsPC-1 cells compared to THP-1 cells, a result
not so surprising since AsPC-1 cells are known as highly resis-
tant to common cytotoxic drugs as well as other cancer stem cell
lines are.53,54 According to the percentage of Annexin V positive
events, O2 displayed the highest activity, as previously seen on
THP-1 cells, but on AsPC-1 cell line the peak activity starts only
at 75 mM (Fig. S1 and S3, ESI†). While treatment of THP-1 cells
with O6 resulted in a signicant percentage of necrosis as noted
above, on AsPC-1 cells it induced agglomeration of double-
stained cells with a very small percentage of Annexin V single-
stained events (Fig. S3, ESI†). A striking lack of gradual intro-
ducing of cells from early to late phases of apoptosis seen in
AsPC-1 samples treated with O2 and O6, is highly indicative as
double-stained events were actually belonging to necrotic cells.
For this reason, compounds O2 and O6 were withdrawn from
further investigation on relying mechanisms of apoptotic death
in THP-1 and AsPC-1 cells.
Concentration–dependent changes in cell cycle distribution
suggest on multi-target drugs. The technical solution that was
applied in this study implies that both apoptosis and cell cycle
analysis were assayed on the very same treated samples and
non-treated controls. This allows a highly precise assessment
with maximally reduced inconsistencies consequent to separate
incubation arrangements. Thus, it highlights any proximate
relationship between alterations in cell cycle distribution and
incidence of cell death for each concentration of investigated
compounds. Cell cycle changes have been evaluated on samples
of THP-1 and AsPC-1 cells that were previously conrmed for
apoptotic response to the treatments (Fig. S1 and S3, ESI†).
In general, all evaluated compounds, at some concentration
level, did induce accumulation of THP-1 cells in the G1-to-S
transition point, while most of them caused concentration–
dependent uctuations in arrangement of cells within phases of
mitotic division. As represented in Fig. 1A, treatment of THP-1
cells with S1 applied in a wide range (from 1 up to 100 mM)
resulted in a concentration–dependent uctuation in cell cycle104766 | RSC Adv., 2016, 6, 104763–104781distribution. In the samples treated with its lowest concentra-
tion, S1 stimulated cell accumulation at the G2/M phase. At 10
mM cells were arrested at the G1-to-S transition point accom-
panied with a signicant incidence of apoptotic death, while
starting from the sample subjected to the concentration of 30
mM, cells shied to the G0/G1 block and sustained up to the
highest 100 mM concentration. Although it might seem that the
samemechanism of activity caused cell cycle arrest at the G0/G1
phase, percentage of apoptotic cells and concentration–
response curve indicate otherwise. The highest percentage of
cells at the G0/G1 phase was found in the samples treated with
S1 at concentrations of 30 and 50 mM, which dened the peak of
the bell-shaped curve (Fig. S2B†). In the samples subjected to 75
and 100 mM magnitude of the G0/G1 block slightly decreased,
followed by a notably reduced frequency of apoptotic cells. This
decrease in pro-apoptotic activity might indicate that S1 at
higher concentration levels emerged additional mechanism of
action that antagonized with the one dominating at concen-
trations between 30 and 50 mM.This journal is © The Royal Society of Chemistry 2016
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View Article OnlineAnother compound that induced variations in the cell cycle
distribution in concentration–dependent manner was S4
(Fig. 1A). Similarly to S1, S4 initially induced THP-1 cells to
slightly accumulate at the G2/M phase that was modestly rising
concentration-dependently within a range from 0.5 to 1 mM. The
incidence of apoptotic death at those concentration levels was
meaningless (Fig. S1, ESI†). However, starting from the sample
treated with S4 at 3 mM, percentage of cells at the G2/M phase
began to decrease followed by accumulation at the G1-to-S
transition point and was accompanied with signicant
increase in incidence of apoptotic death. Finally, at the highest
concentration (30 mM) a G0/G1 block was recorded together
with almost halved percentage of apoptosis as compared to
concentration of 10 mM. It is interesting to emphasize that S1
and S4 have more similarity in terms of transitive changes
within cell cycles than their corresponding bis-TCH S2 and
mono-TCH S3 analogues, respectively. Although S1 and S4 are
not structurally correlated and diﬀer in number of aromatic
rings as well as in position of the side chain attached to the
hetero-aromatic ring, those molecules share comparable tran-
sitive changes within cell cycle distribution. However, that was
not the case with their structural counterparts, S2 and S3
(Fig. 1A). Namely, S2 and S3 at lower concentration levels
induced accumulation at the G1-to-S transition point, then
progress toward a gathering of cells at the S phase. In the case of
the compounds with hydroxyl group (S5 and S6), a negligible
variations in a cell cycle distribution were seen in the samples
treated with concentrations that induced apoptosis in THP-1
cells (Fig. 1A and S1, ESI†). Both those treatments resulted in
accumulation of cells at the G1-to-S transition point at
concentration of 30 mM, which in samples subjected to S5 was
getting intensied following the rise of applied concentration,
whereas in cells treated with S6 a concentration–dependent
accumulation of cells at the S phase was seen.
In AspC-1 cells concentration–dependent uctuations in cell
cycle distribution was seen in samples treated with S2 (Fig. 1B).
Accumulation of treated cells at the G2/M phase seen in the
samples treated with S2 at concentration of 1 mM was accom-
panied with low incidence of apoptosis (Fig. S3, ESI†). At next
concentration levels of 10 and 30 mM, arrest at the S phase
became dominant alteration followed by gradually reduced
percentage of cells at the G2/M phase. This switch in cell cycle
arrest was accompanied with increased occurrence of apoptotic
death. However, rise in percentage of cells at the G0/G1 phase,
which started at 50 mM, coincided with decreased percentage of
apoptosis, especially in the sample treated with concentration
of 75 mM. While treatment of THP-1 cells with S6 triggered
accumulation at the S phase followed by an increased rate of
apoptosis (Fig. 1A and S1, ESI†), in AsPC-1 cells, the same
treatment induced the reversed outcome (Fig. 1B and S3, ESI†).
At the concentration range from 10 to 50 mM S6 inducted
a modest percentage of AsPC-1 cells into apoptosis, whereas at
concentrations of 75 and 100 mM it resulted in the highest
apoptotic response but did not cause any signicant alteration
in cell cycle distribution when compared to non-treated control.
The classical concept of concentration–response relation-
ship indicates that the interaction between applied drugThis journal is © The Royal Society of Chemistry 2016concentration and caused eﬀect in treated biological model is
assumed sigmoidal. Sigmoidal or threshold model of concen-
tration–response curve implies that drugs at low concentrations
do not have signicant biological eﬀect, while with rise of
concentrations the eﬀect linearly increases till the saturation is
reached. Increasing number of evidences emerge that threshold
model of concentration-related response does not adequately
explain all aspects of drug activity. Instead, biphasic or hor-
metic concentration–response model has been shown as far
more appropriate to describe pharmacodynamics features of
many drugs used for the treatment of cancer.55–57
Despite a large base of published evidences that support
biphasic model, to our best knowledge there are only few
studies dealing with the underlying cause of non-sigmoidal
response, and both had docetaxel as the subject of investiga-
tion.58,59 Hermandez-Vargas et al.59 were following changes in
cell death, cell cycle, and gene transcription inMCF-7 andMDA-
MB-231 breast cancer cell lines aer treatment with docetaxel.
Their results revealed that docetaxel targeted diﬀerent phases of
cell cycle according to drug concentration, whereas a biphasic
growth–response curve was in consistence with the existence of
at least two diﬀerent mechanisms of docetaxel's activity. Later
on, another group of authors concluded that biphasic dose–
response gained aer treatment of prostate cancer cell lines
with docetaxel was occurred due to mitotic catastrophe at low
concentrations, while apoptosis was the cause of cell death at
concentrations higher than 10 mM.58 Additionally, Szomolay and
Shahrezaei55 proposed a model where alterations in phosphor-
ylation–dephosphorylation cycles due to diﬀerent speeds of
phosphatase and kinase activity can result in a variety of dose–
response behaviors.
In the current study, we report overlapping and coincidental
variations in cell cycle changes followed by altered intensity in
apoptotic responses, characterized by biphasic concentration–
response curves for compounds S1 and S4. Other investigated
compounds displayed as well concentration–dependent rear-
rangements of cells within mitotic division, but those were not
accompanied with oscillations in apoptotic response and
consequential biphasic curve. At the present, we cannot ratio-
nally propose bio-molecular reasons for the described results,
but we can undoubtedly state that our compounds targeted
diﬀerent phases of cell cycle depending on their concentration.
According to those facts, our compounds can be indicated as
those with polypharmacological proles, which implies on
a single drug that is acting on multiple cellular targets.60 This
type of drugs oﬀers several advantages over standard drug
combination and the main of them include easer dose titration
and evasion of serious drug interactions regarding their toxi-
cological proles, metabolism and excretion. Therefore, recog-
nition of biological molecules targeted by current compounds
will be the subject of our further investigations.
Positive relationship between structural similarity and cas-
pases dependency of apoptotic death. Relaying on results of
pro-apoptotic activity, which showed superiority of TCHs, the
focus of our attention in the course of investigation on caspases
activity was directed toward assessment of structure–activity
relationship between pairs of corresponding mono- and bis-RSC Adv., 2016, 6, 104763–104781 | 104767
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View Article OnlineTCHs. Firstly, we wanted to dene was the apoptosis induced by
our compounds caspase-dependent or not. For that matter, we
applied two assays with intention to determine to which extent
apoptosis was dependent upon caspases' activation, as well as
which of the two main caspases pathways were activated due to
the particular treatment. Co-incubation with pan-caspase
inhibitor during 6 h incubation provided the information on
the extent of caspases' implication in the process of apoptotic
death induced by investigated compounds. Comparison of the
percentages of apoptotic and necrotic events between samples
co-treated with Z-Val-Ala-Asp (OMe) uoromethylketone
(Z-VAD-fmk) and those treated with investigated compound
only revealed the amplitude of inhibited apoptotic deaths, as
well as consequential shiing in the incidence of necrosis, both
as a result of interrupted caspases cascades. Despite the fact
that caspases have no role in the process of necrotic death, there
are two ways in which co-incubation with Z-VAD-fmk can alters
the incidence of necrotic events in respect to compound single-
treated samples. First, increased percentage of necrotic cells in
the Z-VAD-fmk co-treated sample reveals that the investigated
compound generated forceful pro-apoptotic stimuli which
could not be executed due to aborted activation of caspases
pathways and cells had to end in necrosis. Second, reduced
percentage of necrotic cells in Z-VAD-fmk co-treated samples
indicates that necrosis in compound single-treated samples
came out as a result of aponecrosis, while the mechanism
responsible for triggering of apoptotic death was not that
assertive as in the previous example and cells were restrained
from slipping into necrosis. Although recorded change in inci-
dences of apoptosis and necrosis induced by co-treatment
with Z-VAD-fmk for the same compound are not algebraically
compatible, it is recommended to follow alterations of the
both types of cell death in order to get more accurate insight
into extent of caspase-dependency during the process of
apoptotic death.
Evident correlation between structure and degree of caspase
dependency of apoptotic process in THP-1 cells induced by the
treatment with investigated compounds was found in two pairs
of mono- and corresponding bis-TCHs (Fig. S4A, ESI†). There
were almost the same percentages of inhibited apoptotic events
by co-incubation with Z-VAD-fmk between counterparts S3 and
S4 (25 8% and 24 8%, respectively), as well as between S5 and
S6 (45  12% and 42  12%, respectively), together with strong
compliance regarding proportions of inhibited early and late
apoptotic events. However, while in the case of S5 and S6 simi-
larity was evident also in relation of inhibited incidence of
necrotic deaths (34 4% and 42 12%, respectively), Z-VAD-fmk
in the samples subjected to S3 drastically increased the
percentage of necrotic events compared to the samples treated
with S4 (221  65% and 4.0  0.6%, respectively). The only
pair of mono- and bis-TCHs that did not show a strong equiva-
lence regarding dependency in caspases activities and apoptosis
is S1 and S2. While co-incubation with Z-VAD-fmk and S2
resulted with poorly reduced incidence of apoptotic cells (28 
14%), the addition of pan-caspase inhibitor almost completely
inhibited apoptosis promoted by the treatment with S1 (81.2 
0.3%). Incompatibility regarding induction of caspases activation104768 | RSC Adv., 2016, 6, 104763–104781between these two compounds was also determined concerning
inuence of Z-VAD-fmk on the frequency of necrotic events. It is
obvious that contrary to hydroxyl derivate S5, another two mono-
TCHs, S1 and S3, have substantially challenged survival of THP-1
cells thus those had to end in necrosis, which was not the case
with their bis-TCH counterparts.
Interestingly, apoptosis in AsPC-1 cells due to the treatment
with S2 revealed as more caspase-dependent (43  16%)
compared to its eﬀect on the THP-1 cells, with necrosis almost
equivalently reduced in both cell lines by the treatment with Z-
VAD-fmk (Fig. S4B, ESI†). Quite contrary, process of apoptotic
death triggered by S6 in AsPC-1 cell line was less caspase-
dependent (32  4%) than in THP-1 cells, together with
slightly stimulated necrotic events. These results indicate those
two compounds most probably drove THP-1 and AsPC-1 cells to
apoptotic death by diﬀerent mechanisms, or in other words,
their activities were phenotype specic.
Activation of caspase-8 was a prevailing trend in treated
cells. Two main caspase pathways are involved in the process of
apoptotic death in eukaryotic cells.61 The extrinsic pathway,
mediated by caspase-8, is activated either by triggering of
specic transmembrane receptors or by endoplasmic reticulum
stress.62 The intrinsic pathway, mediated by caspase-9, is acti-
vated as a result of bioenergetics and metabolic catastrophe.
The assay we applied enables to concomitantly follow activation
of those two caspase pathways in the same sample, where
percentage of cells with single activated caspase-8 or -9 in regard
to non-treated control indicates on which of these pathways
were stimulated upstream.
Strong correlation in apoptosis caspase-dependency found
between mono- and bis-TCHs has been repeated in the assay of
caspase-8 and -9 activation. The most impressive is almost the
same pattern in assortment of cells with activated calspase-8, -9,
or both between samples treated with S3 and S4 (Fig. 2A). It is
important to accentuate that these two compounds signicantly
suppressed caspase-9 activation, which strongly indicates that
apoptosis induced in THP-1 cells by S3 and S4 has not been
driven by intrinsic apoptotic pathway. Prominent similarity was
clearly obvious for another pair of mono- and bis-TCHs.
Namely, S1 and S2 were the only compounds that displayed
diverse level of caspase-dependency on THP-1 cells (Fig. S4A,
ESI†), while here both induced signicant increase in
percentage of cells with activated caspase-8 only andmoderately
reduced percentage of cells with single activated caspase-9
(Fig. 2A). The addition of hydroxyl group on aromatic ring
resulted in a slight diﬀerence in caspases' activation between
samples treated with mono- and bis-TCHs S5 and S6 respec-
tively. Compound S5 was the only one not markedly increasing
the percentage of cells with activated caspase-8, but rose
proportion of cells with single activated caspase-9 although not
signicantly compared to non-treated control.
However, another repeating occurrence became evident
when comparing the eﬀects of mono- and bis-homologs: in all
samples subjected to bis-TCHs, the percentages of cells
expressing both caspase-8 and -9 were considerably higher
compared to samples treated with their mono-counterparts
(Fig. 2A). A cross talk that exists between extrinsic andThis journal is © The Royal Society of Chemistry 2016
Fig. 2 Induction of caspase-8 and -9 activation in THP-1 cells (A) and AsPC-1 cells (B), determined after 6 h incubation with investigated
compounds applied at their ED50 concentrations. Results are presented as themean SD percentage of cells that expressed activated caspase-8
only, caspase-9 only, and both caspases of two replicates from independent experiments.
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View Article Onlineintrinsic apoptotic pathways allows them to activate each other.
Thus, active caspase-9 cleaves and further activates caspase-3
that subsequently in a feedback amplication loop activates
caspase-8.63 Otherwise, activated caspase-8 via bid processing
propels mitochondrial outer membrane permeabilization with
cytochrome c release. The latter is involved in formation of
apoptosome together with apoptotic protease activating factor
1 (APAF1), ATP and pro-caspase-9, which results in the activa-
tion of caspase-9.61 As was reviewed above, with exception of
compound S5, all mono- and bis-TCHs primarily triggered
activation of caspase-8, but the percentages of cells with both
activated caspases in samples treated with S1 and S3 were on
the level of non-treated control that makes quite possible these
two ligands interfered with the cross-talk activation of caspase-
9. On the other hand, in THP-1 cells treated with S5 and S6,
almost the same percentages of cells with both active caspases
were determined, while in cells subjected to S5 caspase-8
was activated subsequently to caspase-9.
Likewise assayed in THP-1 cells, activation of caspase-8
dominates in AsPC-1 samples treated by bis-TCHs S2 and S6
(Fig. 2B). However, S2 in AsPC-1 cells also initiated activation of
caspase-9 independently of caspase-8, while S6 reducedThis journal is © The Royal Society of Chemistry 2016caspase-9 activity compared to non-treated control. These
results reinforce the assumption stated above on phenotype
specic mechanisms of S2 and S6 activities.
Mono-TCHs revealed higher pro-oxidant activity. Currently,
there are two opposing therapeutic strategies that employ ROS to
beat the cancer. One of them supports the use of ROS-scavenging
compounds that are capable to abolish ROS signaling and
therefore inhibit tumor growth. However, apart from experi-
mental evidences which shown that antioxidants decreased
antitumor activity of anticancer agents such as paclitaxel, bor-
tezomib and radiation therapy,64–66 more importantly are results
of clinical trial which revealed that use of several antioxidants
were associated with increased cancer evidence.67 The other
approach implies the use of agents that increase ROS generation.
Interestingly, results of preclinical studies with ROS-generating
agents showed selective antitumor toxicity.65,68,69
Mitochondria are a signicant source of ROS, together with
endoplasmic reticulum and peroxisomes.70 Here, we have
investigated pro-oxidant properties of all our compounds that
induced apoptotic cell death in THP-1 and AsPC-1 cell lines, by
following their ability to induce superoxide formation in mito-
chondria using MitoSOX Red uorescent tracker. AlthoughRSC Adv., 2016, 6, 104763–104781 | 104769
Fig. 3 Mitochondrial superoxide radical production in THP-1 cells (A),
AsPC-1 cells (B), and in both cell lines subjected to O2 (C). All inves-
tigated compounds were added in concentration of 50 mM during 6 h
of incubation. Histograms present distribution of MitoSox Red positive
cells in non-treated controls (thin line) and treated cells (thick line) with
the mean  SD percentage of cells positive for ROS in two treated
replicates from independent experiments.
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View Article Onlineselectivity of MitoSOX Red toward superoxide radicals has been
questioned by Zielonka and colleagues,71,72 other authors
demonstrated its specicity and conrmed ability for site-
specic detection of mitochondrial superoxides.73,74
Basal production of ROS was very similar in the both cell
lines when expressed as percentage of ROS-producing cells, (5.4
 0.6% for THP-1 and 8.4  0.3% for AsPC-1). In THP-1 cells,
considerably higher pro-oxidative activity was obtained aer
mono-TCHs S1 and S3 treatments as compared to their bis-
structural analogues S2 and S4 (Fig. 3A). Less striking discrep-
ancy in ROS-generating ability was revealed for S5 and S6.
Considering structural features, S1, S3 and S5 have highly
reactive –NH–NH2 group that is probably in relation to their
increased pro-oxidant capacity. On the other hand, –OH group
attached to the quinoline ring of S6 contributed to a ROS-
generating capacity in comparison to other bis-TCHs S2 and
S4. However, two hydroxyl groups in S6 could not raise the ROS-
producing potential to the level of mono-TCHs. Moreover, quite
intriguing results were obtained with treatment of AsPC-1 cells
by S2 and S6 as they were the only TCHs that revealed pro-
apoptotic activity on this cell line (Fig. 2B). While there was
almost no diﬀerence comparing percentages of ROS-positive
cells in THP-1 and AsPC-1 samples treated with S6, treatment
of AsPC-1 cells with S2 resulted in signicantly higher ampli-
tude of ROS production than in THP-1 cell line. This particular
outcome with S2 cannot be put in relation to its structure, but
only as another proof for phenotype-specic activity with no
rational explanation that can be given so far.
Although O2 was excluded from detailed analysis on mech-
anisms involved in apoptotic death, we chose here to explore its
pro-oxidant activity and compare these results with those of its
structural analogue S2. In THP-1 cells O2 induced a four-fold
higher ROS production than S2 (Fig. 3A and C). From the
point of structure–activity relationship, oxygen placed in O2
instead of sulfur in S2 may be considered as the cause for
increased pro-oxidant activity of O2. On the other hand, O2, as
well as S6, gave the equivalent result on AsPC-1 and THP-1 cells
(Fig. 3A–C). This outcome additionally underlines phenotype-
specic pro-oxidant activity of S2, which deserves further
detailed experimental analysis. Furthermore, by comparing
mitochondrial ROS-generating activity and apoptotic responses
in THP-1 and AsPC-1 cell lines (Fig. S1 and S3, ESI†), the lack of
clear correlation between these two cellular events become
obvious. Compounds S2, S4 and S6, which were strong pro-
apoptotic inducers compared to their mono-TCHs counter-
parts, reveal here less pro-oxidant activity. Compound O2
inducing high percentage of ROS-positive cells on both cell lines
triggers necrotic cell death and not apoptosis. Finally, signi-
cant discrepancy in mitochondrial ROS production found in
THP-1 and AsPC-1 cells treated with S2, is in reverse proportion
with incidence of apoptotic death. The only interdependency in
relation of high ROS generation was seen in AsPC-1 cells treated
with S2 that also displayed accelerated activation of caspase-9,
previously conrmed as associated mechanisms by which
oxidative stress initiates apoptotic death.75 Prevailing activation
of caspase-8 in the majority of investigated samples (Fig. 2),
together with the fact that treatment with S2 induced poor104770 | RSC Adv., 2016, 6, 104763–104781apoptotic response in AsPC-1 cells, strongly indicates that
mitochondrial ROS formation did not play an important role in
triggering apoptosis in THP-1 and AsPC-1 cells.This journal is © The Royal Society of Chemistry 2016
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View Article OnlineBis-TCHs revealed ability to induce reprogramming of CSC
phenotype in AsPC-1 cells. For the use of drugs in combination
for cancer treatment, among the leading reasons, the rst
remains to avoid fast development of tumor resistance.
However, acquired resistance occurs over time for almost every
drug, unless the therapy is curative. Development of insuscep-
tibility to treatment relies on intra-tumor heterogeneity where
resistant sub-clones drive cancer progression, as previously
explained above. The discovery that some of our compounds
induce a strong apoptotic response in the used CSC model,
together with their ability to target diﬀerent phases of cell cycle
in a concentration–dependent manner, strongly indicated
a multi-target mode of activity. Thus, we wanted to test their
potential to induce diﬀerentiation in AsPC-1 cells. For this
experiment, we chose compounds S2 and S6, the two inducing
apoptosis in AsPC-1 cells. Additionally, compound S4 was
included as the only molecule (among three bis-TCHs) that did
not reveal pro-apoptotic activity on these CSCs.
AsPC-1 cells were incubated over 72 h with low concentra-
tions of the investigated compounds, and aerwards stained
with anti-CD44s-FITC in order to follow possible changes in
expression of this stemness CSCs surface marker.76,77 CD44 is
a transmembrane glycoprotein that serves as a receptor for
various components of extracellular matrix.78,79 Its most
important roles include intermediation in cell–cell and cell–
matrix interactions, as well as cancer cell migration. Thus, CD44
binding regulates CSCs survival, self-renewal, and chemo-
resistance.79,80 Our experimental results were analyzed
regarding two parameters: percentage of positive CD44 cells,
and the median uorescent intensity (MFI) expressed in arbi-
trary units (AU) for CD44-positive cells subgroup. Thus
computed MFI represents median incidence of CD44 expres-
sion per cell, irrespectively of size of CD44-positive population.
In non-treated AsPC-1 samples, 89  3% of cells were
expressing CD44 with aMFI of 3416 43 AU. In cells subjected to
S2 and S6 at concentration of 10 mM, a slight reduction of the
number of CD44-positive subpopulation was recorded (Fig. S5A
and B, ESI†). This eﬀect was accompanied with decrease in MFI
to 2918  91 AU and 2396 167 AU for the samples treated with
S2 and S6, respectively. These changes in MFI signify that the
applied treatments down-regulate the number of CD44 receptors
per cell. At concentration of 1 mM, S2 and S6 signicantly drop-
ped the percentages of CD44-positive cells. Compound S6
accomplished the best response, whereas MFI values were still
a bit higher (1876 120 AU) compared to samples treated with S2
(1711  42 AU). On the contrary, compound S4, the one that did
not achieve apoptotic response in AsPC-1 cells, now revealed an
ability to induce their diﬀerentiation with inverse concentration-
dependency matching to the two other compounds (Fig. S5C,
ESI†). It is interesting to note that S4 at 10 mM accomplished the
greatest down-regulation of CD44 expression according to MFI
values (1522 48 AU). These results suggest that our compounds
may have the ability to stimulate reprogramming of AsPC-1 cells
independently of any pro-apoptotic activity, and thus should be
further studied by following the expression of other CSC
phenotype markers like Oct4, Nanog or Sox2.81This journal is © The Royal Society of Chemistry 2016Activity on tumor spheroids. Tumor spheroids are 3D culture
models that in vitromimic in vivomalignant tissue in respect to
multiple parameters such as drug concentration, molecular
weight, kinetics, charge, solubility, diﬀusion, oxygenation,
metabolism, and sequestration.82 As they are, spheroids serve as
a valuable screening platform for advanced evaluation of anti-
cancer drug eﬀectiveness with exception of their inuence on
response of the immune system (also the case for xenogras in
nude mice) and on angiogenesis. Most spheroids derived from
CSCs are compact globes with concentric zones clearly distin-
guished within, which growing is characterized by regular
increase in diameters.83 However, AsPC-1 cells create spheres of
irregular shape without recognizable zones inner their struc-
ture.46 Their growth is erratic, does not primarily comprise the
enlargement in diameters but rather formation of satellite
spheres that highly look like metastatic propagation. For that
reason, growth recording in our study of non-treated or treated
spheroids has been performed by computation and summation
of surface areas for all tumor masses in each well.
Activities of four compounds, which did induce cell death in
the 2D AsPC-1 model irrespectively of apoptosis or necrosis,
were evaluated (Fig. S3, ESI†). The 3D spheres were treated for
eight days, and compounds were tested in three concentrations
(1, 10 and 100 mM). Here are reviewed only results for concen-
trations that at the day 8 achieved a reduction of spheroid size
when compared to day 0 (growth rate < 1, Fig. 4).
Growth of non-treated spheres recorded a linear rate, with
a maximal increase of 1.5  0.3 fold at day 8. Compound O6 was
the only one eﬀective in two evaluated concentrations. While at
concentration of 10 mM O6 successfully inhibited growth of
tumor mass, at 100 mM it reduced tumor mass to a half of its
initial size aer six days of incubation. The second most
successful treatment was at 100 mM for O2 as the only compound
which activity was described with a steadily downhill growth rate
curve, with the tumor sizes at the day 8 equal to those subjected
to O6 at 100 mM. It is important to notice that both O6 and
O2 were withdrawn from further investigations due to results of
Annexin V/PI staining, considering both of them induced
necrotic death, a situation that in vivo induce inammation thus
not suitable for any putative drug. Furthermore, in 2D model
samples treated with O2, at the same concentration, more than
89% of cells were double-stained, while O6 was relatively less
eﬃcient. Similarly to those treated with O2, spheres exposed to
S6 were continually losing size until day 6. The most surprising
was the activity of S2, a compound which on 2Dmodel at 100 mM
triggered apoptotic death in less than 25% of the population. On
3D culture, S2 displayed a delayed response, which was docu-
mented with slight gain in size of treated spheres during the rst
four days, that was followed by signicant collapse of their
masses undoubtedly caused by signicant incidence of cell
death. Therefore, for S2, according to results on 2D model, it
might be proclaimed as compound of no interest regarding
treatment of AsPC-1 cells. Here S2 revealed as almost equally
eﬀective as tumor growth inhibition of S6. This result is an
excellent testimonial for the use of 3D cultures in drug screening
as it is more accurate and closer to in vivo situation.RSC Adv., 2016, 6, 104763–104781 | 104771
Fig. 5 Changes in absorption spectrum of S2 after addition of HSA. All
concentrations are given in mM. Spectra are recorded in 30 mM
phosphate buﬀered saline (PBS), pH 7.36.
Fig. 6 Changes in ﬂuorescence emission spectra of HSA (c¼ 7 107
M) upon addition of S2 in following concentrations: (0.0; 0.35; 0.7; 1.4;
2.1; 2.8; 3.5; 4.9, 6.3)  106 M; T ¼ 310 K; 30 mM PBS, pH ¼ 7.4.
Fig. 4 Changes in size andmorphology of AsPC-1 3D culture over the
8 day treatment period (A). Images have been acquired every other
day, starting from day 0 on the Celigo imaging cytometer using Celigo
software. Scale bar: 500 mm. Growth rates of non-treated and treated
AsPC-1 spheroids over the time of experiment (B).
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View Article OnlineInteraction between S2 and human serum albumin (HSA)
HSA is well known for its ligand binding capacity and repository
for an extraordinarily diverse range of molecules whichmakes it
an important factor in the pharmacokinetic behavior of many
drugs by aﬀecting their eﬃciency and rate of delivery. Its feature
to accumulate in solid tumors raises interest of medicinal
chemists to explore ability of newly synthesized compounds to
bind to and use HSA as a carrier, and yields the rationale for
developing the albumin-based drug delivery systems for tumor
targeting drugs.84 Here we explored performed experimental
and docking analysis protocol to obtain information on selected
TCH S2 interaction with HSA.
Criterions used to choose the compound for evaluation of
HSA binding were pro-apoptotic activity on both investigated104772 | RSC Adv., 2016, 6, 104763–104781cell lines and lipophilicity as one of the most important factors
involved in the extent of drug binding.85 Although log P was
argued as not reliable physicochemical descriptor to distin-
guish strong and weak binders among diverse ligands,86 its
higher value dened for S2 was the rational to investigate its
binding properties rather than for S6 (Table S5, ESI†). Binding
of S2 to HSA was studied by UV/Vis spectroscopy. Aer the
addition of HSA to the solution of S2, blue shi of absorption
maximum was observed (Fig. 5). More details about the HSA–S4
binding were obtained from uorescence titration experiments
and molecular docking.
Fluorescence spectroscopy. The changes in emission spec-
trum of HSA during titration with the increasing amount of S2
are shown in Fig. 6. Signicant decrease of HSA uorescence
intensity (uorescence quenching) is observed during titration,
with the blue shi of maximum emission at 340 nm. The blue
shi of the maximum emission wavelength indicates that theThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinemicroenvironment around Trp214 is altered as HSA–S2 complex
is formed.
With the increasing amount of quencher, results may deviate
from the linearity due to instrumental inner lter eﬀect. This
eﬀect was removed applying Lakowicz procedure, eqn (1).
Fcorr ¼ Fobs  10
AexþAem
2 (1)
where Fcorr and Fobs are corrected and observed uorescence
intensities, and Aex and Aem are absorbancies at the excitation
and emission wavelengths, respectively.87 Corrected uores-
cence intensities were used for all calculations.
Fluorescence data were processed using double log plot,
according to the eqn (2).
log
F0  F
F
¼ log Kb þ n log½Q (2)
where F0 and F have the same meaning as in previous equation;
Kb is binding constant, and n is the number of independent
binding sites for molecule. Linear dependence for quenching
data recorded at 310 K is shown in Fig. 7, and the results of
linear t for three temperatures are given in Table 3.
Fluorescence quenching is classied as static or dynamic.
Dynamic quenching is highly dependent upon diﬀusion.
Higher temperatures result in faster diﬀusion and hence larger
values for biomolecular quenching constant. On the other
hand, higher temperatures will typically result in the dissocia-
tion of weakly bound complexes, and therefore decrease the
biomolecular quenching constant in static process. The KbTable 3 Binding constants (Kb) and the number of binding sites for
binding of S2 to HSA at three temperatures
T (K) Kb (M
1)  104 log Kb n r2
293 8.5  2.2 4.9  0.1 0.82  0.02 0.995
301 6.1  2.8 4.8  0.2 0.78  0.04 0.986
310 4.6  0.8 4.7  0.1 0.77  0.01 0.998
Fig. 7 Double-log plot for determination of binding constant Kb, and
the number of binding sites n for HSA–S2 interaction.
This journal is © The Royal Society of Chemistry 2016value decreases with the increase of temperature, which is an
indication of static quenching mechanism.
Compound S2 binds to approximately one binding site, as
suggested with the value of n. The log Kb is in the range optimal
for biologically active compounds.88–90 These results suggest
that S2 strongly binds to HSA, so it can be eﬀectively carried and
stored in the human body.
Thermodynamic parameters of binding. The enthalpy (DH)
and entropy change (DS) during the binding of small molecule
to protein can be determined measuring the binding constants
at several temperatures, and following the Van't Hoﬀ eqn (3):
ln Kb ¼ DH
RT
þ DS
R
(3)
where R is the universal gas constant, T is the temperature (in
K), and Kb is the binding constant at the corresponding
temperature. Results are shown in Fig. 8 and Table 4.
According to Ross' view,91 the signs and magnitudes of
thermodynamic parameters for protein reactions can account
for the main forces contributing to protein stability. From the
thermodynamic stand-point, DH > 0 and DS > 0 implies
a hydrophobic interaction,DH < 0 andDS < 0 reects the van der
Waals force or hydrogen bond formation and DH < 0 and DS >
0 suggesting an electrostatic force.
The negative enthalpy and negative entropy indicate that the
van der Waals forces or hydrogen bonding are dominant for
HSA–S2 binding. Process is enthalpically driven, and hydrogen
bonds between HSA and S2 are the most important intermo-
lecular forces.
Molecular docking of S2 with HSA. To explore the binding
mode of S2 to HSA, docking of S2 into the sites IB, IIA and IIIAFig. 8 The plot of ln Kb vs. 1/T for the interaction of S2 with HSA.
Table 4 Thermodynamic parameters of S2 binding to HSA
T (K) ln Kb (M
1)
DG
(kJ mol1)
DH
(kJ mol1)
DS
(J mol1 K1)
293 11.38 27.731 28.731 3.55
301 11.02 27.584
310 10.74 27.670
RSC Adv., 2016, 6, 104763–104781 | 104773
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View Article Onlinewas performed. The binding energies are given in Table 5.
Compound S2 favorably interacts with the binding site IIA.
The most favorable docking solution for each binding site is
shown in Fig. 9. S2 has many polar interactions within the site
IIA of HSA. It makes hydrogen bonds with the residues His242Fig. 9 S2 (orange) docked into the site IB (top), IIA (middle), and IIIA
(bottom) of HSA. Amino acid residues, which interact with the S2 are
shown as sticks and colored by atom. The most important polar
interactions are highlighted as green dots, together with corre-
sponding distances.
Table 5 Docking scores of S2 into the three sites of HSA
Binding site
(PDB code)
Binding aﬃnity
(kcal mol1)
IB (4LB2) 9.0
IIA (3LU7) 11.0
IIIA (2BXE) 9.7
104774 | RSC Adv., 2016, 6, 104763–104781(at distance 3.3 A˚), Arg222 (2.3–2.45 A˚), Lys199 (2.8 A˚) as well as
Trp214 (3.2 A˚). Hydrophobic and/or p–p stacking interactions
between AB39 and Phe211 and Trp214 are also possible. Lesser
number of polar interactions are observed for AB39 binding
into the sites IB and IIIA.
Binding mode of S2 into the site IIA of HSA conrms the
dominant contribution of hydrogen bonding in overall binding
energy.
Conclusion
Results of the current study validate superior anti-cancer activity
of TCHs over CHs. Used set of biological tests provides prelimi-
nary information on mechanism of their activity. Particularly
attractive is their ability to target diﬀerent phases of mitotic
division in concentration–dependent manner, which for some
compounds was overlapping with alterations in intensity of
apoptotic response of treated cells. That information strongly
indicate on multi-target activity prole of investigated TCHs.
Furthermore, apoptosis induced by these compounds was not
exclusively caspase-dependent, while activation of caspase-8 was
assayed as the principal trend signifying on endoplasmic retic-
ulum stress or even activation of death receptor signaling as the
triggering incident of apoptotic death. Induction of ROS genesis
in mitochondria was shown to be trivial accident since there was
no obvious correlation between potency in ROS production and
intensity of apoptotic response. Among tested compounds, only
two bis-TCHs also revealed pro-apoptotic activity on CSCs, while
two bis-CHs induced necrotic death on this cell model. However,
investigation on 3D spheroidal CSC model that is a superior
platform for testing the drug activity compared to standardly
used 2D monolayer, gave more accurate perspective on anti-
tumor activity of evaluated drugs. According to those data,
compound S6 as the only TCH that revealed strong pro-apoptotic
activity on AsPC-1 2D model, showed on spheroids a sustained
antitumor activity with signicantly reduced size of treated
spheres compared to their initial volume. Moreover, compound
S6 drastically reduced percentage of CD44 positive CSCs over the
3 day incubation time, and therefore displayed its ability to act
also as a pro-diﬀerentiation agent at low concentrations levels.
Those results strongly encourage additional study of mono- and
bis-TCHs, withmechanism of caspase-8 activation as the primary
interest in any further investigations.
Experimental
Reagents and instrumentation
2-Quinolinecarboxaldehyde ($98%), thiocarbohydrazide
(98%) and carbohydrazide ($98%) were obtained from Sigma.
8-Quinolinecarboxaldehyde (98%) and 8-hydroxy-2-
quinolinecarboxaldehyde (98%) were obtained from Acros
Organics. All solvents (reagent grade) were obtained from
commercial suppliers and used without further purication.
Elemental analyses (C, H, N, S) were performed by the
standard micromethods using the ELEMENTAR Vario EL III
CHNS/O analyzer. Fourier-transform infrared (FTIR) spectra
were obtained using FTIR BOMEM MB 100 in the form ofThis journal is © The Royal Society of Chemistry 2016
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View Article OnlineKBr pellets. FTIR spectra (Fig. S5 and S6, ESI†) were recorded in
the transmission mode between 400 and 4000 cm1 with
a resolution of 4 cm1. Abbreviations used for IR spectra: vs,
very strong; s, strong; m, medium; w, weak. All NMR spectral
measurements were performed on a Bruker Avance III
500 spectrometer equipped with a broad-band direct probe. The
spectra were recorded at room temperature in DMSO-d6.
Chemical shis are given on d scale relative to tetramethylsilane
(TMS), as internal standard for 1H and 13C. Coupling constants
(J) were expressed in Hz. Abbreviations used for NMR
spectra: s, singlet; dd, doublet of doublets; ddd, double double
doublet. 1D (1H and 13C) and 2D (COSY, NOESY, 1H–13C HSQC
and 1H–13C HMBC) spectra of all compounds are shown in
Fig. S8–S79 (ESI†) together with the atom numbering scheme
(Table S1, ESI†).Synthesis of compounds
General procedure for the preparation of mono (thio)car-
bohydrazones O1, O3, O5, S1, S3, S5
Example: 8-quinolinealdehyde carbohydrazone (O1). Solution
of 8-quinolinecarboxaldehyde (0.0785 g, 0.5 mmol) in ethanol
(10 mL) was added into hot solution of dhO (0.0901 g, 1 mmol)
in ethanol (40 mL). Aer the catalytic amount of conc. hydro-
chloric acid was added, reaction mixture was stirred and
reuxed for 3 h. The resulting precipitate was collected by
ltration and washed successively with cold ethanol and
diethyl ether. Yellow solid was recrystallized from absolute
methanol. Yield: 0.0733 g (64%). Mp 185 C. Elemental anal-
ysis calcd for C11H11N5O (Mw ¼ 229.24 g mol1): C, 57.63; H,
4.84; N, 30.55%; found: C, 57.71; H, 4.78; N, 30.62%. IR (KBr,
cm1) nmax: 3316s (NH2), 3200s (NH), 3096m (CHaryl), 1681vs
(C]O), 1621m (C]N); 1H NMR (500.26 MHz, DMSO-d6)
d (ppm): 4.12 (s, 2H, H–N5), 7.57 (dd, 1H, H–C3, 3J3,4 ¼ 8.3 Hz,
3J3,2¼ 4.1 Hz), 7.63 (t, 1H, H–C6, 3J6,5¼ 3J6,7¼ 7.4 Hz), 7.98 (dd,
1H, H–C5, 3J5,6 ¼ 7.8 Hz, 4J5,7 ¼ 1 Hz), 8.16 (s, 1H, H–N4), 8.39
(dd, 1H, H–C4, 3J4,3 ¼ 8.3 Hz, 4J4,2 ¼ 2.0 Hz), 8.58 (d, 1H, H–C7,
3J7,6 ¼ 7.4 Hz), 8.94 (dd, 1H, H–C2, 3J2,3 ¼ 4.1 Hz, 3J2,4 ¼ 2.0
Hz), 9.14 (s, 1H, H–C9), 10.65 (s, 1H, H–N3). 13C NMR (126.0
MHz, DMSO-d6) d (ppm): 121.67 (C3), 125.61 (C7), 126.45 (C6),
127.94 (C4a), 128.90 (C5), 131.59 (C8), 136.55 (C4), 136.89 (C9),
145.01 (C8a), 150.08 (C2), 157.21 (C10).
2-Quinolinealdehyde carbohydrazone (O3). O3 was synthesized
similarly to O1, starting from 2-quinolinecarboxaldehyde and
dhO. White solid was recrystallized from absolute methanol.
Yield: 56%. Mp 183 C. Elemental analysis calcd for C11H11N5O
(Mw ¼ 229.24 g mol1): C, 57.63; H, 4.84; N, 30.55%, found: C,
57.58; H, 4.62; N, 30.69%. IR (KBr, cm1) nmax: 3297s (NH2),
3188s (NH), 3084m (CHaryl), 1679vs (C]O), 1638m (C]N).
1H
NMR (500.26 MHz, DMSO-d6) d (ppm): 4.15 (s, 2H, H–N5), 7.58
(ddd, 1H, H–C6, 3J6,7 ¼ 8.2 Hz), 7.74 (ddd, 1H, H–C7, 3J7,6 ¼ 8.2
Hz), 7.93–7.99 (br.m.ovlp., 2H, H–C5, H–C8), 8.03 (s, 1H, H–C9),
8.27 (d, 1H, H–C4, 3J4,3 ¼ 8.4 Hz), 8.34–8.46 (br.m.ovlp., 2H, H–
C3, H–N4, 3J3,4 ¼ 8.4 Hz), 10.84 (s, 1H, H–N3). 13C NMR (126.0
MHz, DMSO-d6) d (ppm): 118.03 (C3), 126.84 (C6), 127.66 (4a),
127.92 (C5), 128.69 (C8), 129.82 (C7), 136.19 (C4), 140.64 (C9),
147.26 (C8a), 154.34 (C2), 156.76 (C10).This journal is © The Royal Society of Chemistry 20168-Hydroxy-2-quinolinealdehyde carbohydrazone (O5). O5 was
synthesized similarly to O1, starting from 8-hydroxy-2-
quinolinecarboxaldehyde and dhO. Yellow solid was recrystal-
lized from absolute methanol. Yield: 72%. Mp 214–215 C.
Elemental analysis calcd for C11H11N5O2 (Mw¼ 245.24 g mol1):
C, 53.83; H, 4.525; N, 28.56%; found: C, 53.66; H, 4.68; N,
28.74%. IR (KBr, cm1) nmax: 3371s (OH), 3335s (NH2), 3198s
(NH), 3049m (CHaryl), 1696vs (C]O), 1600m (C]N).
1H NMR
(500.26 MHz, DMSO-d6) d (ppm): 4.14 (s, 2H, H–N5), 7.08 (dd,
1H, H–C7, 4J7,5 ¼ 1.4 Hz), 7.36 (dd, 1H, H–C5, 4J5,7 ¼ 1.4 Hz),
7.41 (m, 1H, H–C6), 8.09 (s, 1H, H–C9), 8.24 (d, 1H, H–C4, 3J4,3¼
8.55 Hz), 8.30–8.50 (br.m.ovlp., 2H, H–C3, H–N4, 3J3,4 ¼ 8.55
Hz), 9.71 (s, 1H, OH), 10.88 (s, 1H, H–N3). 13C NMR (126.0 MHz,
DMSO-d6) d (ppm): 111.59 (C7), 117.74 (C5), 118.35 (C3), 127.73
(C6), 128.52 (C4a), 136.06 (C4), 137.93 (C8a), 140.50 (C9), 152.25
(C2), 153.24 (C8), 156.83 (C10).
8-Quinolinealdehyde thiocarbohydrazone (S1). S1 was synthe-
sized similarly to O1, starting from dhS instead of dhO. Yellow
solid was recrystallized from water/ethanol mixture (1 : 4, v/v).
Yield 75%. Mp 163–164 C. Elemental analysis calcd for
C11H11N5S (Mw ¼ 245.30 g mol1): C, 53.86; H, 4.52; N, 28.55; S,
13.07%; found: C, 53.75; H, 4.64; N, 28.40; S, 13.22%. IR (KBr,
cm1) nmax: 3438s (NH), 3249w (NH2), 2921m (CHaryl), 1500vs
(amide II); 1237m (C]S). 1H NMR (500.26 MHz, DMSO-d6)
d (ppm): 4.91 (s, 2H, H–N5), 7.59 (dd, 1H, H–C3, 3J3,2 ¼ 4.15 Hz,
3J3,4 ¼ 8.35 Hz), 7.65 (t, 1H, H–C6, 3J6,5 ¼ 7.9 Hz, 3J6,7 ¼ 7.25 Hz),
8.03 (dd, 1H, H–C5, 3J5,6 ¼ 7.9 Hz), 8.41 (dd, 1H, H–C4, 3J4,3 ¼
8.35 Hz), 8.73 (d, 1H, H–C7, 3J7,6 ¼ 7.25 Hz), 8.96 (dd, 1H, H–C2,
3J2,3 ¼ 4.15 Hz), 9.30 (s, 1H, H–C9), 9.95 (s, 1H, H–N4), 11.67 (s,
1H, H–N3). 13C NMR (126.0 MHz, DMSO-d6) d (ppm): 121.75 (C3),
126.33 (C7), 126.40 (C6), 127.94 (C4a), 129.59 (C5), 131.21 (C8),
136.59 (C4), 138.97 (C9), 145.30 (C8a), 150.29 (C2), 175.96 (C10).
2-Quinolinealdehyde thiocarbohydrazone (S3). S3 was synthe-
sized similarly to O1, starting from 2-quinolinecarboxaldehyde
and dhS. Yellow solid was recrystallized from absolute ethanol.
Yield: 56%. Mp 183 C. Elemental analysis, calcd for C11H11N5S
(Mw ¼ 245.30 g mol1): C, 53.86; H, 4.52; N, 28.55; S, 13.07%;
found: C, 53.66; H, 4.48; N, 28.32; S, 13.17%. IR (KBr, cm1)
nmax: 3425m (NH), 3267s (NH2), 2962w (CHaryl), 1500vs (amide
II); 1230s (C]S). 1H NMR (500.26 MHz, DMSO-d6) d (ppm): 4.97
(s, 2H, H–N5), 7.59 (ddd, 1H, H–C6, 3J6,7 ¼ 8.2 Hz), 7.75 (ddd,
1H, H–C7, 3J7,6¼ 8.2 Hz), 7.97 (dd, 2H, H–C5, H–C8), 8.18 (s, 1H,
H–C9), 8.34 (d, 1H, H–C4, 3J4,3 ¼ 8.7 Hz), 8.52 (d, 1H, H–C3,3J3,4
¼ 8.7 Hz), 10.18 (s, 1H, H–N4), 11.78 (s, 1H, H–N3). 13C NMR
(126.0 MHz, DMSO-d6) d (ppm): 118.00 (C3), 126.75 (C6), 127.46
(4a), 127.57 (C5), 128.40 (C8), 129.57 (C7), 135.89 (C4), 141.98
(C9), 146.97 (C8a), 153.68 (C2), 175.37 (C10).
8-Hydroxy-2-quinolinealdehyde thiocarbonohydrazone (S5). S5
was synthesized similarly to O1, starting from 8-hydroxy-2-
quinolinecarboxaldehyde and dhS. Yellow solid was recrystal-
lized from DMF/methanol mixture (1 : 9, v/v). Yield 83%. Mp
208–209 C. Elemental analysis calcd for C11H11N5OS (Mw ¼
261.30 g mol1): C, 50.56; H, 4.24; N, 26.80; S, 12.27%; found: C,
50.42; H, 4.34; N, 28.77; S, 12.42%. IR (KBr, cm1) nmax: 3450s
(OH), 3424s (NH), 3165m (NH), 3015m (CHaryl), 1503vs (amide
II); 1228s (C]S). 1H NMR (500.26 MHz, DMSO-d6) d (ppm): 4.96RSC Adv., 2016, 6, 104763–104781 | 104775
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View Article Online(s, 2H, H–N5), 7.09 (dd, 1H, H–C7, 3J7,6¼ 7.65 Hz, 4J7,5¼ 1.1 Hz),
7.37 (dd, 1H, H–C5, 3J5,6 ¼ 7.9 Hz, 4J5,7 ¼ 1.1 Hz), 7.42 (t, 1H, H–
C6, 3J6,5 ¼ 7.9 Hz, 3J6,7 ¼ 7.6 Hz), 8.23 (s, 1H, H–C9), 8.27 (d, 1H,
H–C4, 3J4,3 ¼ 8.7 Hz), 8.52 (d, 1H, H–C3, 3J3,4 ¼ 8.7 Hz), 9.80 (s,
1H, OH), 10.17 (s, 1H, H–N4), 11.84 (s, 1H, H–N3). 13C NMR
(126.0 MHz, DMSO-d6) d (ppm): 112.00 (C7), 117.71 (C5), 118.65
(C3), 127.97 (C6), 128.71 (C4a), 136.03 (C4), 138.10 (C8a), 142.16
(C9), 151.95 (C2), 153.36 (C8), 175.72 (C10).
General procedure for the preparation of bis-(thio)carbohy-
drazones O2, O4, O6, S2, S4, S6
Example: bis-(8-quinolinealdehyde) carbohydrazone (O2).
Solution of 8-quinolinecarboxaldehyde (0.33 g, 2.1 mmol) in
ethanol (10 mL) was added into hot solution of dhO (0.0901 g, 1
mmol) in ethanol (40 mL). Aer the catalytic amount of conc.
hydrochloric acid was added, reaction mixture was stirred and
reuxed for 3 h. The resulting precipitate was collected by
ltration and washed successively with cold ethanol and diethyl
ether. Yellow solid was recrystallized from absolute methanol.
Yield: 0.199 g (54%). Mp 219–220 C. Elemental analysis calcd
for C21H16N6O (Mw ¼ 368.14 g mol1): C, 68.47; H, 4.38; N,
22.81%; found: C, 68.32; H, 4.91; N, 22.73%. IR (KBr, cm1)
nmax: 3331s (NH), 3055m (CHaryl), 1707vs (C]O), 1614w (C]N).
1H NMR (500.26 MHz, DMSO-d6) d (ppm): 7.61 (dd, 2H, H–C3]
H–C17, 3J3,2 ¼ 3J17,18 ¼ 4.1 Hz, 3J3,4 ¼ 3J17,16 ¼ 8.3 Hz); 7.72 (t,
2H, H–C6]H–C14, 3J6,5 ¼ 3J14,15 ¼ 7.9 Hz); 8.04 (dd, 2H, H–
C5]H–C15, 3J5,6 ¼ 3J15,14 ¼ 7.9 Hz); 8.43 (dd, 2H, H–C4]H–
C16, 3J4,3¼ 3J16,17¼ 8.3 Hz, 4J4,2 ¼ 4J16,18 ¼ 1.75 Hz); 8.60 (d, 2H,
H–C7]H–C13); 8.99 (dd, 2H, H–C2]H–C18, 3J2,3 ¼ 3J18,17 ¼
4.1 Hz, 4J2,4 ¼ 4J18,16 ¼ 1.75 Hz); 9.50 (s, 2H, H–C9]H–C11);
11.09 (s, 2H, H–N3, H–N4). 13C NMR (126.0 MHz, DMSO-d6)
d (ppm): 121.77 (C3]C17); 125.72 (C7]C13); 126.49 (C6]C14);
128.02 (C4a]C15a); 129.28 (C5]C15); 131.65 (C8]C12);
136.62 (C4]C16); 139.89 (C9]C11); 145.19 (C8a]C12a),
150.16 (C2]C18); 152.28 (C10).
Bis-(2-quinolinealdehyde) carbohydrazone (O4). O4 was
synthesized similarly to O2, starting from 2-quinolinecarbox-
aldehyde and dhO, with a slight modication of previously
published procedure.47 White solid was recrystallized from
DMF/methanol mixture (1 : 9, v/v). Yield 78%. Mp 162–164 C.
Elemental analysis calcd for C21H16N6O (Mw ¼ 368.14 g mol1):
C, 68.47; H, 4.38; N, 22.81%; found: C, 68.81; H, 4.80; N, 22.56%.
IR (KBr, cm1) nmax: 3392s (NH), 3096m (CHaryl), 1708vs (C]O),
1630w (C]N). 1H NMR (500.26 MHz, DMSO-d6) d (ppm): 7.63
(ddd, 2H, H–C6]H–C16, 3J6,7 ¼ 3J16,17 ¼ 6.8 Hz, 3J6,5 ¼ 3J16,15 ¼
8.2 Hz), 7.79 (ddd, 2H, H–C7]H–C17, 3J7,6 ¼ 3J17,16 ¼ 6.8 Hz),
8.02 (ddd, 4H, H–C5]H–C15, H–C8]H–C18, 3J5,6 ¼ 3J15,16 ¼
8.2 Hz), 8.31 (s, 2H, H–C9]H–C11), 8.38–8.60 (br.m.ovlp., 4H,
H–C3]H–C13, H–C4]H–C14), 11.31 (s, 2H, H–N3]H–N4). 13C
NMR (126.0 MHz, DMSO-d6) d (ppm): 117.78 (C3]C13), 127.11
(C7]C17), 127.79 (C6]C16), 127.99 (C4a]C14a), 128.84 (C5]
C15), 130.00 (C8]C18), 136.47 (C4]C14), 144.06 (C9]C11),
147.35 (C8a]C18a), 151.67 (C2]C12), 153.99 (C10).
Bis-(8-hydroxy-2-quinolinealdehyde) carbohydrazone (O6). O6
was synthesized similarly to O2, starting from 8-hydroxy-2-
quinolinecarboxaldehyde and dhO. Yellow solid was recrystal-
lized from DMF/methanol mixture (1 : 9, v/v). Yield: 66%. Mp
248–249 C. Elemental analysis calcd for C21H16N6O3 (Mw ¼104776 | RSC Adv., 2016, 6, 104763–104781400.39 g mol1): C, 62.99; H, 4.03; N, 20.99, %; found: C, 62.84;
H, 4.11; N, 21.22%. IR (KBr, cm1) nmax: 3408s (OH), 3230m
(NH2), 3116m (NH), 2925m (CHaryl), 1684vs (C]O), 1601w (C]
N). 1H NMR (500.26 MHz, DMSO-d6) d (ppm): 7.12 (dd, 2H, H–
C7]H–C17, 3J7,6 ¼ 3J17,16 ¼ 7.4 Hz, 4J7,5 ¼ 4J17,15 ¼ 1.5 Hz), 7.41
(dd, 2H, H–C5]H–C15, 4J5,7 ¼ 4J15,17 ¼ 1.5 Hz), 7.45 (t, 2H, H–
C6]H–C16, 3J6,7 ¼ 3J16,17 ¼7.4 Hz), 8.17–8.39 (br.m.ovlp., 4H,
H–C3]H–C13, H–C4]H–C14), 8.48 (s, 2H, H–C9]H–C11),
9.80 (s, 2H, H–O1]H–O2), 11.34 (s, 2H, H–N3]H–N4). 13C
NMR (126.0 MHz, DMSO-d6) d (ppm): 112.13 (C7]C17), 117.90
(C5]C15), 118.12 (C3]C13), 128.13 (C6]C16), 128.75 (C4a]
C14a), 136.40 (C4]C14), 138.13 (C8a]C18a), 144.02 (C9]
C11), 151.92 (C2]C12), 153.37 (C8]C18), 162.45 (C10).
Bis-(8-quinolinealdehyde) thiocarbohydrazone (S2). S2 was
synthesized similarly to O2, starting from dhS instead of dhO.
Yellow solid was recrystallized from DMF/ethanol mixture (1 : 4,
v/v). Yield 75%. Mp 192–193 C (decomp.). Elemental analysis
calcd for C21H16N6S (Mw ¼ 384.12 g mol1): C, 65.61; H, 4.19; N,
21.86; S, 8.34%; found: C, 65.44; H, 4.03; N, 21.77; S, 8.21%. IR
(KBr, cm1) nmax: 3441m (NH), 3119w (CHaryl), 1519vs (amide II);
1231s (C]S). 1H NMR (500.26 MHz, DMSO-d6) d (ppm): 7.62
(dd, 2H, H–C3]H–C17, 3J3,4 ¼ 3J17,18 ¼ 4.1 Hz), 7.75 (t, 2H, H–
C6]H–C14, 3J6,5 ¼ 3J14,15 ¼ 7.95 Hz), 8.09 (dd, 2H, H–C5]H–
C15, 3J5,6 ¼ 3J15,14 ¼ 7.95 Hz), 8.35–8.64 (br.m.ovrl. 3H, H–C4]
H–16, H–C13), 8.88 (s, H–C7), 9.00 (dd, 2H, H–C2]H–C18, 3J2,3
¼ 3J18,17¼ 4.1 Hz), 9.48 (s, 1H, H–C11), 9.91 (s, 1H, H–C9), 12.14
(d, 2H, H–N3]H–N4). 13C NMR (126.0 MHz, DMSO-d6) d (ppm):
121.85 (C3]C17), 125.98 (C13), 126.48 (C6]C14), 126.70 (C7),
128.01 (C4a]C15a), 129.99 (C5]C15), 130.97 (C12), 131.46
(C8), 136.65 (C4]C16), 140.36 (C8a]C12a), 140.48 (C11),
145.40 (C9), 150.34 (C2]C18), 175.21 (C10).
Bis-(2-quinolinealdehyde) thiocarbohydrazone (S4). S4 was
synthesized similarly to O2, starting from 2-quinolinecarbox-
aldehyde and dhS, with a slight modication of previously
published procedure.47 Yellow solid was recrystallized from
DMSO/methanol mixture (9 : 1, v/v). Yield 68%. Mp 184 C.
Elemental analysis calcd for C21H16N6S (Mw ¼ 384.12 g mol1):
C, 65.61; H, 4.19; N, 21.86; S, 8.34%; found: C, 65.78; H, 4.01; N,
21.56; S, 8.12%. IR (KBr, cm1) nmax: 3424s (NH), 2923m (CHaryl),
1488vs (amide II); 1229s (C]S). 1H NMR (500.26 MHz, DMSO-
d6) d (ppm): 7.67 (ddd, 2H, H–C6]H–C16,
3J6,7 ¼ 3J16,17 ¼
7.05 Hz, 3J6,5 ¼ 3J16,15 ¼ 7.95 Hz), 7.82 (ddd, 2H, H–C7]H–C17,
3J7,6 ¼ 3J17,16 ¼ 7.05 Hz), 8.06 (ddd, 4H, H–C5]H–C15, H–C8]
H–C18, 3J5,6¼ 3J15,16¼ 7.95 Hz), 8.20 (s, 1H, H–C11), 8.40 (s, 1H,
H–C9), 8.46–8.63 (br.m.ovlp., 4H, H–C3]H–C13, H–C4]H–
C14), 12.16 (s, 1H, H–N4), 12.51 (s, 1H, H–N3). 13C NMR (126.0
MHz, DMSO-d6) d (ppm): 118.41 (C13), 118.72 (C3), 127.75 (C6]
C16), 128.23 (C4a]C14a), 127.37 (C5]C15), 130.47 (C7]C17),
130.47 (C8]C18), 136.98 (C4]C14), 144.46 (C11), 149.59 (C9),
147.70 (C8a]C18a), 152.03 (C12), 153.96 (C2), 175.97 (C10).
Bis-(8-hydroxy-2-quinolinealdehyde) thiocarbohydrazone (S6).
S6 was synthesized similarly to O2, starting from 8-hydroxy-2-
quinolinecarboxaldehyde and dhS. Yellow solid was recrystal-
lized from DMF/methanol mixture (1 : 9, v/v). Yield 74%; mp
240–241 C. Elemental analysis calcd for C21H16N6O2S (Mw ¼
416.46 g mol1): C, 60.56; H, 3.87; N, 20.18; S, 7.70%; found: C,
60.68; H, 4.03; N, 20.07; S, 7.52%. IR (KBr, cm1) nmax: 3479sThis journal is © The Royal Society of Chemistry 2016
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View Article Online(OH), 3428m (NH), 2923m (CHaryl), 1500vs (amide II); 1231s
(C]S); 1H NMR (500.26 MHz, DMSO-d6) d (ppm): 7.14 (d, 2H,
H–C7]H–C17, 3J7,6 ¼ 3J17,16 ¼ 7.4 Hz), 7.43 (m, 4H, H–C5]H–
C15, H–6]H–16), 8.05–8.41 (br.m.ovlp., 4H, H–C3]H–C13, H–
C4]H–C14), 8.53 (s, 1H, H–C11), 8.89 (s, 1H, H–C9), 9.89 (s, 2H,
O1H]O2H), 12.18 (s, 1H, H–N4), 12.52 (s, 1H, H–N3). 13C NMR
(126.0 MHz, DMSO-d6) d (ppm): 112.24 (C7]C17), 117.87 (C5]
C15), 118.62 (C3]C13), 128.38 (C6]C16), 128.90 (C4a]C14a),
136.48 (C4]C14), 138.20 (C8a]C18a), 143.85 (C11), 149.17
(C9), 151.60 (C2]C12), 153.44 (C8]C18), 175.61 (C10).DFT theoretical calculations, NMR and lipophilicity
predictions
Initial conformations of compounds O1–O6 and S1–S6 were
generated in OMEGA 2.4.3,90 using MMFF94s force eld.92 The
structures were additionally optimized using uB97X-D func-
tional,93 and 6-311G(d,p) basis set. The solvation eﬀect was
simulated with polarized continuum model (PCM),94 of aceto-
nitrile. In order to conrm that the obtained geometry repre-
sents the global minimum, vibrational frequency analysis was
performed aerward (Opt + Freq keywords). No imaginary
frequencies were found, so stationary point reached do repre-
sent global minimum. Diﬀerent tautomeric forms and
geometric isomers around azomethine (C]N) bond(s) were
modeled, and the lowest energy form of each compound was
(thio)keto, with E conguration on every C]N bond. Starting
from global minimum found, NMR chemical shis are calcu-
lated on uB97X-D/6-311G(d,p) level using GIAO approxima-
tion,95 applying PCM model of DMSO. Chemical shis are
scaled to 1H and 13C chemical shis of TMS. Lipophilicity of
compounds was predicted starting from DFT-optimized geom-
etries, calculating virtual log P derived from molecular lip-
ophilicity potential.96Free radical scavenging antioxidant assay
The proton donating ability was assayed using a protocol for the
determination of radical scavenging activity.50 Compounds were
dissolved in DMSO and were diluted into ten diﬀerent
concentrations. Commercially available DPPH radical was dis-
solved in methanol at a concentration of 6.58  105 M. Into
a 96-well microplate, 140 mL of DPPH solution was loaded and
10 mL DMSO solution of the tested compounds was added, or
pure DMSO (10 mL) as the control. The microplate was incu-
bated for 30 min at 298 K in the dark and the absorbance was
measured at 517 nm using a Thermo Scientic Appliskan. All
themeasurements were carried out in triplicate. The scavenging
activity of the compounds was calculated using the eqn (4):
Scavenging activityð%Þ ¼

Acontrol  Asample

Acontrol
 100 (4)
where Asample and Acontrol refer to the absorbances at 517 nm of
DPPH in the sample and control solutions, respectively. IC50
values were calculated from the plotted graph of scavenging
activity against the concentrations of the samples. IC50 is
dened as the total antioxidant concentration necessary to
decrease the amount of the initial DPPH radical by 50%. IC50This journal is © The Royal Society of Chemistry 2016was calculated for all compounds based on the percentage of
DPPH radicals scavenged. Ascorbic acid was used as the refer-
ence compound (positive control) with concentrations 50 to
500 mg mL1.
Cell cultures
The two ATCC cell lines were all purchased from LGC Standards
(Molsheim, France). Human pancreatic adenocarcinoma (AsPC-
1, ATCC® CRL-1682) cell line was maintained in DMEM high
glucose medium (Dominique Dutscher, 67172 Brumath cedex,
France, Cat. no. L0102-500), while human acute monocytic
leukemia cell line (THP-1, ATCC® TIB-202) was maintained in
RPMI-1640 (Life Technologies, Paisley, UK, Cat. no. 11875-093),
supplemented with 10% (v/v) heat inactivated fetal bovine
serum (FBS, Life Technologies, Paisley, UK, Cat. no. 10270-106)
and 1% (v/v) penicillin–streptomycin (10 000 units per mL and
10 000 mg mL1, Life Technologies, Paisley, UK, Cat. no. 15140-
122). Cells were kept at 37 C in humidied atmosphere con-
taining 5% (v/v) CO2 during their exponential growing phase
and in the course of incubation with investigated compounds.
Investigated compounds were initially dissolved in DMSO to
the stock concentration of 20 mM. Further dilutions to the
experimental concentrations applied on the cells have been
done with RPMI-1640 or DMEMmedia immediately before each
experiment, thus the nal concentration of DMSO on cells
treated with the highest applied concentration of investigated
compound was 0.5% (v/v).
Annexin V and PI staining
Cells were seeded in 96 at bottom well plates (Corning®
Costar®, Cat. no. CLS3596) in a volume 0.1 mL, at a density of
10 000 per well. AsPC-1 cells were le overnight to settle, while
treatment of THP-1 cells started 2 h aer seeding. Investigated
compounds were added in a range of six concentrations. As
controls, non-treated cells, cells treated with 0.5% DMSO, and
cells treated with celastrol (Enzo Life Sciences, Cat. no. ALX-350-
332-M025) at 50 mM concentration were used.
Aer 24 h of treatment, supernatant medium with non-
adherent cells were removed from plate with AsPC-1 cells and
placed into another 96 well plate. Fresh PBS was added to
remaining adherent cells aerwards the plate was centrifuged
at 450 g for 10 min. Supernatant was discarded and 200 mL of
trypsin–EDTA (BioWest, Nuaille, France, Cat. no. L0930-100)
was added to each well. Cells were detached in about 15
minutes of incubation at 37 C. Trypsin–EDTA was removed
aer additional spinning cycle, aerwards previously removed
supernatant with non-adherent cells were added to trypsinized
cells and stained with Annexin V-FITC (Immuno Tools, Frie-
soythe, Germany, Cat. no. 31490013) and PI (Miltenyl Biotec Inc,
Auburn, USA, Cat. no. 130-093-233) in a volumes of 3 mL. In the
case of THP-1 cells, Annexin V-FITC and PI were added to the
wells with cells right aer the incubation time was over.
Plates were analyzed onGuava® easyCyte 12HTBenchtop ow
microcapillary cytometer (Millipore, Merck, Darmstadt, Ger-
many) using the dedicated InCyte® soware package. Cells were
classied according to Annexin V-FITC (green uorescence) andRSC Adv., 2016, 6, 104763–104781 | 104777
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View Article OnlinePI (red uorescence) labeling on viable (double negative), pre-
apoptotic cells (Annexin V-FITC single-stained cells), necrotic
cells (PI single-stained cells), and cells in advanced phases of
apoptosis (double-stained cells). Described trypsinization
protocol was applied each time AsPC-1 cells were prepared for
ow cytometry analyses, unless is stated otherwise.
Calculation of ED50 concentration
Percentages of Annexin V single-stained and double-stained
cells were summarized for each concentration of investigated
compound. The computed percentages were plotted against
corresponding concentrations on a concentration–response
graph. ED50 concentration was calculated as the one that
corresponds to half-way of the sigmoidal concentration–
dependent curve using asymmetric ve-parameter logistic
equation (GraphPad Prism 6 soware).
Cell cycle analysis
Distribution of cells within phases of mitotic division has been
evaluated on remaining cells aer Annexin V/PI analysis, which
right aer the read out was nished were xed in ethanol over-
night at 4 C. Before reading, plates were centrifuged on 450 g for
10min, ethanol was discarded and PBS added in a volume of 100
mL per well. Cells were stained with 50 mL of FxCycle™ PI/RNAse
staining solution (Molecular Probes, Cat. no. F10797), and
incubated at 37 C for 30 min. Plates were analysed on Guava®
easyCyte 12HT Benchtop owmicrocapillary cytometer using the
dedicated InCyte® soware package.
Inhibition of caspase activity
Cells were treated with investigated compound at ED50 concen-
tration for 6 h with or without pan-caspase inhibitor Z-VAD-fmk
(Promega, Madison, USA, Cat. no. G7232). Z-VAD-fmk was added
in a concentration that was previously tested and conrmed as
non-toxic to cells over 6 h incubation (10 mM and 20 mM for THP-
1 and AsPC-1 cell line, respectively). As controls, non-treated
cells, cells treated with Z-VAD-fmk only, and cells treated with
ED50 concentration only were used. Aer incubation period was
ended, treated cells were carried out for Annexin V/PI staining as
described above, and analyzed on Guava® easyCyte 12HT
Benchtop ow microcapillary cytometer using the dedicated
InCyte® soware package. The percent of apoptosis inhibited by
Z-VAD-fmk co-treatment was determined using eqn (5):
Apoptosis inhibitionð%Þ ¼

1

% apoptosis in A
% apoptosis in B

 100
(5)
where A is the sample treated with Z-VAD-fmk and investigated
compound at its ED50 concentration, while B is the corre-
sponding sample treated only with the same investigated
compound at ED50 concentration.
Caspase-8 and caspase-9 activities
Cells were treated with investigated compound at ED50
concentration for 6 h aerwards activity of caspase-8 and -9104778 | RSC Adv., 2016, 6, 104763–104781were assayed by means of Guava Caspase 9 SR and Caspase
8 FAM kit (EMD Millipore, Cat. no. 4500-0640), following
manufacturer's instructions. Cells were analysed on Guava®
easyCyte 12HT Benchtop ow microcapillary cytometer using
the dedicated InCyte® soware package. In acquired data cells
were discriminated according to expression of caspase-8 (Grn-B
uorescence), caspase-9 (Yel-B uorescence), and 7-AAD (Red-B
uorescence).
Generation of radical oxygen species in mitochondria
Cells were treated over 6 h with investigated compounds in
a concentration of 50 mM, aerwards were stained with MitoSox
Red (Molecular Probes, Cat. no. M36008) according to manu-
facturer's recommendations. Analysis was performed on
Guava® easyCyte 12HT Benchtop ow microcapillary cytometer
using the dedicated InCyte® soware package.
Investigation of pro-diﬀerentiation activity
AsPC-1 cells were seeded in a volume 0.1 mL, at density 5000 per
well of 96 well at bottom plates. Aer 24 h, investigated
compounds were added in a volume of 0.2 mL to the nal
concentrations of 1 and 10 mM per well. Wells with control cells
were supplemented with medium up to the volume of 0.3 mL.
All cells, treated and non-treated controls, were incubated for
another 72 h, aerwards evaluation of changes in expression of
cell surface marker of diﬀerentiation has been performed.
When incubation was ended, cells were trypsinized as described
above. Anti-CD44-FITC antibody (Miltenyi Biotec, Cat. no.
130-095-195) was added in a volume of 1 mM to each well. Non-
treated controls were labeled with anti-CD44-FITC or anti-
IgG-FITC (Miltenyl Biotec, Cat. no. 130-093-192). Plate was
incubated at 37 C for 30 min, when additional spinning cycle
(450 g for 10 min) with PBS removal was performed to remove
the excess of antibodies. Finally, fresh PBS was added to the
wells and cells were analyzed on Guava® easyCyte 12HT
Benchtop ow microcapillary cytometer using the dedicated
InCyte® soware package.
Growth inhibition of 3D tumor models
Three-dimensional AsPC-1 tumor models were made in 96 well
plates (Corning, Sigma-Aldrich, St. Louis, Mo, USA, Cat. no.
4515). Tumors were le to grow for additional four days, aer-
wards investigated compounds were added in concentrations
of 100, 10 and 1 mM. Evaluation has been maintained during 8
day incubation period, with media exchanged on the day 4.
Changes in the tumors sizes have been assessed on Celigo®
imaging cytometer (Cyntellect, Brooks Life Science Systems,
Poway, CA, USA) using Celigo soware. Growth rates of non-
treated and treated spheroids were computed for each day
during 8 day incubation by dividing the area on the day-n with
the area on the day 0.
HSA binding experiments
Fatty acid free HSA (<0.007% fatty acids, Mw ¼ 66 478 Da) was
purchased from Sigma, as well as potassium dihydrogenThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinephosphate, disodium hydrogen phosphate, sodium chloride
and potassium chloride used for PBS preparation. Stock solu-
tion of HSA (c ¼ 1.91  104 M) was prepared by dissolving
accurate weighted mass of commercially available lyophilized
HSA in freshly prepared 1  PBS (pH 7.36), and stock solution
was kept in freezer in 100 mL portions. The stock solution of S2
(c ¼ 6.87  104 M) was prepared by dissolving proper amount
of substance in DMSO, because of its low solubility in buﬀer.
For HSA–S2 interaction studies, HSA solution was freshly
prepared from the stock by dilution with a buﬀer (HSA
concentration was kept constant, c ¼ 7  107 M), and titrated
with S2 stock solution to avoid large sample dilution. Substance
was added in 0.5, 1, 2, 3, 4, 5, 7 and 9 molar equivalents. Aer
each aliquot addition, system was stirred and le to equilibrate
for 15 min before UV-Vis absorption and uorescence emission
spectra recording. Aer addition of nine equivalents of
substance, nal volume of DMSO did not exceeded 2% (v/v). It
was shown that addition of 15% of DMSO did not induce
structural changes in BSA, protein structurally similar to HSA.
Therefore, it is unlikely that the conformation of HSA will be
changed with the level of DMSO used in this study.97 Milipore
water was used in the preparation of buﬀer solution.
Fluorescence measurements were performed on spectrou-
orometer Fluoromax-4 Jobin Yvon (Horiba Scientic, Japan),
equipped with Peltier element for temperature control and
magnetic stirrer for cuvette, using quartz cell with 1 cm path
length and 4 mL volume. Before recording of uorescence
spectrum, diluted HSA solution was ultraltrated using lters
with 0.23 mm pore size. An excitation wavelength was 280 nm,
with 5 nm slits; emission spectra were recorded in 300–450 nm
wavelength range, with 5 nm slits, and 0.1 s integration time.
Background PBS signal was subtracted from each spectrum.
UV-Vis spectra were recorded on a GBC Cintra6 UV/Vis spec-
trophotometer, using quartz cell with 1 cm path length and 4 mL
volume. All spectra were recorded against the corresponding blank
(PBS) in the 250–450 nm wavelength range at room temperature.Molecular docking studies
For exploring the binding of S2 to site IB of HSA, crystal struc-
ture of HSA with idarubicin dimer (PDB code 4LB2) was used.98
For site IIA, PDB structure of indol amide derivative (PDB code
3LU7) was used.99 For site IIIA, structure of HSA–diunisal
complex (PDB code 2BXE) was used.88 To dene the receptor
site, the residues in sphere of 12 A˚ around co-crystallized ligand
were used. Ligands and water molecules were removed prior to
receptor preparation in AutoDock Tools 1.5.6.89 Initial confor-
mation of S2 was generated in OMEGA 2.4.3,90 using MMFF94s
force eld.92 The geometry of lowest energy conformer was
further optimized using semiempirical PM6 method imple-
mented in MOPAC 2016.100 Docking was carried in Autodock
Vina 1.1.2 soware.101 VEGAZZ 3.0.3 was used as a GUI.102Acknowledgements
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